Phase 1 results point to larger trial of enzalutamide and fulvestrant in breast cance

[News]

Results of a multicenter phase 1 clinical trial presented at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with...

More... (http://www.medicalnewstoday.com/releases/303761.php)